Pargol balali retweetledi

In the phase 3 OCEANIC-STROKE trial involving patients with noncardioembolic ischemic stroke or high-risk TIA, asundexian added to antiplatelet therapy led to a lower risk of ischemic stroke without increasing major bleeding. Full trial results: nejm.org/doi/full/10.10…
Editorial: Asundexian for Noncardioembolic Ischemic Stroke nejm.org/doi/full/10.10…

English




























